Robert J. Bitterman, Director at RXi Pharmaceuticals Corp (RXII), bought 5,000 shares at $1.20 ($6K) on 2015-01-22, disclosed to the SEC on 2015-01-23.
Open-market purchase of $6k RXII by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.19 | 1,853 | $2K | 36.9% |
| 2 | $1.20 | 3,147 | $4K | 63.1% |
| Total | $1.20 avg | 5,000 | $6K | 100% |
| Filing → |
| PHIO | BUY | 2026-01-02 | $5K | — | Filing → |
| PHIO | BUY | 2025-12-29 | $5K | — | Filing → |
| PHIO | BUY | 2025-11-24 | $6K | — | Filing → |